The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Key highlights from BTOG 2023: radiotherapy at the forefront
John Conibear, MBBCh, BSc, MSc, MRCP, FRCR, St Barts Health NHST, UK, reflects on his main highlights from the British Thoracic Oncology Group (BTOG) Annual Conference 2023 including data presented from clinical trials that utilized radiotherapy in combination with other therapeutic approaches for the treatment of lung cancer. Dr Coniber discusses the SYSTEMS-2 trial (GN13ON388), which is a phase II study aiming to evaluate whether dose escalation of radiotherapy improves pain control in patients with mesothelioma as well as the SARON (NCT02417662) trial which is reportedly close to completing the recruitment stage of the trial. This interview took place at BTOG 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
